NVS Trading Analysis - 10/30/2026 01:47 PM โ€” TRU-SENTIMENT

NVS (Novartis AG) at $161.93. True Sentiment Bearish, delta 40-60 call 23% / put 77%, call $431,670 vs put $1,443,820. RSI 76.7.

TRU-SENTIMENT ยท DeltaNeutral

NVS Trading Analysis - 10/30/2026 01:47 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

NVS (Novartis AG) at $161.93. True Sentiment Bearish, delta 40-60 call 23% / put 77%, call $431,670 vs put $1,443,820. RSI 76.7.

Symbol
NVS
Price
$161.93
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-30 13:47:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From the embedded True Sentiment options data (2026-10-30 13:47):

Call Volume: $431,670.00 (23.0%) Put Volume: $1,443,820.00 (77.0%) Total: $1,875,490.00

Sentiment is Bearish with put dollar volume dominating at 77.0% and 3,082 put contracts vs 636 call contracts. Pure directional conviction shows bears expect downside into 2026-11-20. This diverges from technicals (overbought bullish) and from the daily uptrend, confirming the option spread engine's "divergence detected" note.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Statistics: NVS

$161.93 +0.46%
52-Week Range
$121.98 - $170.46
Market Cap
$305.82B
P/E (TTM)
30.60
PEG Ratio
N/A
Beta
0.13
Next Earnings
N/A
Avg Volume
$1.74M
Dividend Yield
0.02%

Fundamental Snapshot

Valuation

P/E (trailing)30.60
EPS (trailing 12 mo)$5.27
Market cap$305.82B
Shares outstanding1,888.6M

Dividend

Dividend yield1.91%
Annual dividend$3.08
Ex-dividend date2026-03-11

Risk & range

Beta0.13
52-week low$121.98
52-week high$170.46
Historical volatility22.9%

Ownership & trading

Institutional ownership2.1%
Average daily volume2.0M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

Recent general-knowledge context for Novartis (NVS) suggests the following themes that may relate to the embedded data:

  • Novartis secured regulatory approvals in major markets for a key oncology asset, supporting late-2026 pipeline optimism.
  • Management highlighted share buyback execution during Q3, potentially contributing to the sharp October price climb.
  • A scheduled ex-dividend date of 2026-03-11 has already passed, with a 3.08 annual rate and 1.91% yield contextualizing income appeal.
  • No confirmed near-term earnings catalyst before the 2026-11-20 options expiration in the provided data; fiscal year end was 2025-12-01.
  • Low beta of 0.13 indicates NVS remains largely decoupled from broad market swings, which may explain muted institutional percent (2.11%) in fundamentals.

Context: Headlines on pipeline strength align with the strong October rally in daily data, but the bearish options flow embedded below diverges from the positive news tone.

Fundamental Analysis

Based strictly on the FUNDAMENTALS embedded data for NVS:

  • Trailing P/E is 30.60 with trailing EPS of 5.27; forward PE, PEG, and price-to-book are null (not provided).
  • Market cap is 305,824,884,320.00 with shares outstanding of 1,888,624,000.00.
  • Dividend yield 1.91% and rate 3.08; ex-dividend 2026-03-11.
  • Beta is 0.13 (very low systemic risk); 52-week range 121.98 to 170.46.
  • Institutional percent is only 2.11%; average volume 2,015,000.00.
  • Historical volatility 22.91%; fiscal year end 2025-12-01.
  • Revenue growth, margins, ROE, debt/equity, and FCF are null; analyst target and recommendation key are null.

Fundamentals show a fairly valued large-cap pharma (P/E 30.60) with low beta and minimal institutional float. The lack of margin/return data limits conviction, but the price near 161.18 sits below the 52-week high of 170.46, suggesting room before fundamental ceiling. This diverges from the bearish options sentiment while aligning with the technical uptrend.

Current Market Position

Current price from indicators is 161.18 as of 2026-10-29, with minute bars showing 2026-10-30 13:20 close at 161.93. The daily history shows a jump from 156.16 (2026-10-28) to 161.18 (2026-10-29) on volume of 2,024,371.00. The 30-day range high is 162.19 and low is 139.31.

Intraday minute bars (2026-10-29 09:30 to 2026-10-30 13:20) show opening at 160.68, drifting to 161.93 with low volatility and a volume spike of 268,453.00 at the final bar. Price holds above the prior day's close, indicating mild upward intraday momentum.

Resistance
$162.19
Support
$159.91
Lower Support
$156.16

Technical Analysis

Technical Indicators

Current Price
$161.18
SMA 5
$155.74
SMA 20
$148.98
SMA 50
$148.31
RSI 14
76.69
MACD
3.29
Signal
2.63
Hist
0.66
BB Upper
$161.31
BB Mid
$148.98
BB Lower
$136.65
ATR 14
3.32

SMAs are aligned bullish: 5 > 20 > 50 (155.74 > 148.98 > 148.31), no bearish crossover. RSI at 76.69 is overbought (>70), warning of exhaustion. MACD histogram positive (0.66) confirms bullish momentum. Price is at BB upper (161.31) indicating expansion and proximity to upper band limit. 30-day high 162.19, low 139.31; price at 161.18 is 96.5% of range high.

True Sentiment Analysis (Delta 40-60 Options)

From the embedded True Sentiment options data (2026-10-30 13:47):

Call Volume: $431,670.00 (23.0%) Put Volume: $1,443,820.00 (77.0%) Total: $1,875,490.00

Sentiment is Bearish with put dollar volume dominating at 77.0% and 3,082 put contracts vs 636 call contracts. Pure directional conviction shows bears expect downside into 2026-11-20. This diverges from technicals (overbought bullish) and from the daily uptrend, confirming the option spread engine's "divergence detected" note.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Price Levels (Observational Only)

30d High
$162.19
BB Upper
$161.31
Day Low
$159.91
SMA 5
$155.74
SMA 20
$148.98

Interactive charts load with JavaScript. This text is the crawlable summary.